GLP1R and myocardial infarction: The addition of data from AMPLITUDE-O trial to the seven-trial meta-analysis [5] showed that patients with type 2 diabetes who received GLP-1 agonists had a decreased risk of MACE and decreased individual components (stroke more than myocardial infarction), independently of the structure of these drugs (exendine-4 based or human analogs).